|
Oct 3
|
Several Insiders Invested In Gossamer Bio Flagging Positive News
|
|
Aug 21
|
Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now
|
|
Aug 21
|
Analysts Just Made A Notable Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) Forecasts
|
|
Jul 25
|
Why Is Gossamer Bio, Inc. (GOSS) the Best One-Dollar Stock to Buy Now?
|
|
May 14
|
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
|
|
May 7
|
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
|
|
May 7
|
Gossamer Bio and Chiesi link for pulmonary hypertension treatment
|
|
May 6
|
Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide
|
|
May 6
|
UPDATE 1-Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition
|
|
May 6
|
Gossamer sells rights to drug it hopes can rival a new Merck therapy
|
|
May 6
|
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
|
|
May 3
|
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
|
|
Apr 26
|
Gossamer Bio Decline Means Insider Profits Down To US$17k
|
|
Mar 13
|
13 Best Biotech Stocks To Buy Under $20
|
|
Mar 12
|
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
|
|
Mar 7
|
Should You Buy Gossamer Bio (GOSS) After Golden Cross?
|
|
Mar 5
|
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
|
|
Dec 5
|
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Dec 5
|
Gossamer Bio Appoints Bob Smith as Chief Commercial Officer
|
|
Nov 29
|
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors
|